CTGLF2 Activators
CTGLF2 Activators encompass a range of chemical compounds that facilitate the enhancement of CTGLF2's functional activity through various signaling pathways. Forskolin and Rolipram both act by increasing intracellular cAMP levels, indirectly promoting CTGLF2 activation via the PKA signaling cascade. This cascade triggers phosphorylation events that are central to the function of CTGLF2. Similarly, PMA and Ionomycin influence the protein by activating PKC and increasing calcium levels respectively, both of which lead to the phosphorylation of proteins that could enhance the activity of CTGLF2. While IBMX and Zaprinast elevate levels of cAMP and cGMP, thereby activating PKA and PKG and potentially enhancing CTGLF2 activity, Anisomycin activates JNK signaling which may lead to the phosphorylation of CTGLF2 or related proteins, thus promoting its activity. EMD 57033 acts by increasing the sensitivity of the contractile machinery to calcium, suggesting a potential enhancement of CTGLF2 activity through calcium-dependent pathways.
Further modulating the activity of CTGLF2, Okadaic Acid inhibits protein phosphatases 1 and 2A, resulting in an overall increase in protein phosphorylation, which may contribute to the activation of CTGLF2. LY294002, a PI3K inhibitor, could indirectly enhance CTGLF2 by shifting the balance toward other signaling pathways that promote CTGLF2 activity. SB203580 selectively inhibits p38 MAPK, allowing for potential activation of CTGLF2related pathways. Lastly, KN-93, by inhibiting CaMKII, alters calcium signaling dynamics, which may also lead to the enhancement of CTGLF2's functional activity. By affecting various signaling molecules and pathways, these activators collectively contribute to the functional upregulation of CTGLF2 without necessitating changes in its expression levels or direct activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates intracellular cAMP levels, which can lead to the activation of PKA. PKA then phosphorylates various substrates that can enhance the functional activity of CTGLF2 by promoting its associated signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator that can modulate intracellular signaling pathways, leading to the activation of CTGLF2 by promoting phosphorylation events that enhance its functional activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, which can activate calcium-dependent protein kinases that may phosphorylate CTGLF2 or its associated proteins, thereby enhancing its activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, leading to an increase in cAMP levels, which could enhance CTGLF2 activity through cAMP-dependent signaling pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, elevating cAMP and cGMP levels in cells, which could lead to the enhancement of CTGLF2 activity via PKA or PKG pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast selectively inhibits phosphodiesterase 5, increasing cGMP levels, which can lead to the activation of PKG and subsequent enhancement of CTGLF2 function. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator that can enhance the functional activity of CTGLF2 by activating JNK signaling pathways, which may lead to the phosphorylation of substrates involved in CTGLF2's function. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation levels within the cell and potential enhancement of CTGLF2 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may indirectly enhance CTGLF2 activity by shifting the balance of signaling pathways, potentially leading to the activation of alternate pathways involving CTGLF2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could enhance CTGLF2 activity by inhibiting a competing signaling pathway, thereby potentially allowing for the activation of CTGLF2-related pathways. | ||||||